Biodesix Inc. Announces R&D Roadmap and Marks One‑Year Public Listing Anniversary
Biodesix Inc. (NASDAQ: BDSX) disclosed that it will present its research and development roadmap during a corporate‑day session held at the American Medical Professionals (AMP) Annual Meeting. The presentation will feature collaborative case‑study panels with strategic partners, including Memorial Sloan Kettering Cancer Center and Bio‑Rad Laboratories. The company’s focus remains on non‑small cell lung cancer pretreatment serum tests and laboratory‑analysis services for blood and tissue samples in the United States.
In a separate event, President and CEO Scott Hutton rang the Nasdaq closing bell to celebrate the fifth anniversary of Biodesix’s initial public offering. The ceremony also coincided with the company’s restored compliance with Nasdaq’s listing requirements, following a recent period of non‑compliance.
At the close of trading on 2025‑10‑28, Biodesix’s share price stood at $6.54. The stock has traded between a 52‑week low of $3.44 (2025‑05‑14) and a 52‑week high of $33.40 (2024‑10‑31). The company’s market capitalization is $50,540,000, and it reports a price‑to‑earnings ratio of –1.21.
The forthcoming roadmap presentation is expected to provide insight into Biodesix’s strategic priorities and potential product pipeline expansions. Investors and industry analysts will be watching for updates on the company’s diagnostic tools and equipment, as well as its partnerships that support the development of novel serum‑testing solutions for lung cancer patients.
